Viridian Therapeutics, Inc.
Lumvoa
thyroid eye disease
Resolved
8days ago
Approval decision · Jun 29, 2026
What's at stake
A final FDA approval decision on Lumvoa for thyroid eye disease is expected Jun 29, 2026.
Primary source
· SEC 8-K
verified 15h ago
“Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Ad”